Perspective Therapeutics, Inc. logo CATX - Perspective Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 9
HOLD 2
SELL 0
STRONG
SELL
0
| PRICE TARGET: $13.33 DETAILS
HIGH: $16.00
LOW: $12.00
MEDIAN: $12.00
CONSENSUS: $13.33
UPSIDE: 346.57%

About Perspective Therapeutics, Inc. (https://www.perspectivetherapeutics.com)

Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.

Key Executives

NAME TITLE DOB SALARY
Johan Spoor Chief Executive Officer & Director 1972 $1,102,000 USD
Markus Puhlmann Chief Medical Officer 1966 $737,400 USD
Jonathan R. Hunt Chief Accounting Officer 1967 $611,165 USD
Joel David Sendek CFO & Principal Financial Officer 1967 $574,294 USD
Amos Hedt PGradDip Chief Business Strategy Officer
Andrew Bright Executive Vice President of Brachytherapy
Annie J. Cheng Vice President of Investor Relations 1976
Chris Nenno General Counsel & Corporate Secretary
Michael K. Schultz Chief Science Officer
Shane Cobb Executive Vice President of Operations

Company Peers

Peer analysis pending, check back in 1-2 minutes.